Immune checkpoint inhibitor-associated myasthenia gravis, myositis, and myocarditis overlap syndrome
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immune checkpoint inhibitor-associated myasthenia gravis, myositis, and myocarditis overlap syndrome
Authors
Keywords
Myasthenia gravis, Myocarditis, Myositis, Immune checkpoint inhibitor, Emergency department, irAE
Journal
AMERICAN JOURNAL OF EMERGENCY MEDICINE
Volume 46, Issue -, Pages 51-55
Publisher
Elsevier BV
Online
2021-03-09
DOI
10.1016/j.ajem.2021.03.005
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Myositis-myasthenia gravis overlap syndrome complicated with myasthenia crisis and myocarditis associated with anti-programmed cell death-1 (sintilimab) therapy for lung adenocarcinoma
- (2020) Qian Xing et al. Annals of Translational Medicine
- PD-1 inhibitor-associated severe myasthenia gravis with necrotizing myopathy and myocarditis
- (2019) Hayato So et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
- (2019) Filipe Martins et al. Nature Reviews Clinical Oncology
- Myocarditis in the Setting of Cancer Therapeutics
- (2019) Marc P. Bonaca et al. CIRCULATION
- Fatal adverse events in two thymoma patients treated with anti-PD-1 immune check point inhibitor and literature review
- (2019) Thomopoulou Konstantina et al. LUNG CANCER
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
- (2018) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Myocarditis in Patients Treated With Immune Checkpoint Inhibitors
- (2018) Syed S. Mahmood et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis
- (2018) Javid J Moslehi et al. LANCET
- Immune Checkpoint Inhibitor–Associated Myositis
- (2018) Céline Anquetil et al. CIRCULATION
- Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors
- (2018) Daniel Y. Wang et al. JAMA Oncology
- Presence of antibodies to striated muscle and acetylcholine receptor in association with occurrence of myasthenia gravis with myositis and myocarditis in a patient with melanoma treated with an anti–programmed death 1 antibody
- (2018) T. Shirai et al. EUROPEAN JOURNAL OF CANCER
- Immune Checkpoint Inhibitor Toxicity in 2018
- (2018) Douglas B. Johnson et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Myasthenia gravis: An emerging toxicity of immune checkpoint inhibitors
- (2017) D. Makarious et al. EUROPEAN JOURNAL OF CANCER
- Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan
- (2017) Shigeaki Suzuki et al. NEUROLOGY
- Myasthenic crisis and polymyositis induced by one dose of nivolumab
- (2016) Toshihiro Kimura et al. CANCER SCIENCE
- Myasthenia gravis — autoantibody characteristics and their implications for therapy
- (2016) Nils Erik Gilhus et al. Nature Reviews Neurology
- Clinical Characteristics of Patients With Double-Seronegative Myasthenia Gravis and Antibodies to Cortactin
- (2016) Elena Cortés-Vicente et al. JAMA Neurology
- Acetylcholine receptor binding antibody-associated myasthenia gravis and rhabdomyolysis induced by nivolumab in a patient with melanoma
- (2015) Takushi Shirai et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started